1. Pfizer has exceeded analyst estimates on both top and bottom lines and raised its full-year guidance. 2. Investors have not responded positively to the earnings news due to the significant portion of growth being driven by Covid-19 related products or non-recurring items. 3. Based on a single stage dividend discount model and traditional price multiples, PFE appears undervalued, suggesting the current price level could be attractive for initiating a position.